Teddy V. - Pharma8k's (Page 6)

BioCryst Pharmaceuticals (BCRX) Announces Board Leadership Transition: Hutson Retires, Milano Elected Chair

11 Dec 2025 SEC Filing 8-K Leadership $BCRX

BioCryst Pharmaceuticals (BCRX) Announces Board Leadership Transition: Hutson Retires, Milano Elected Chair

BioCryst Pharmaceuticals (BCRX) announced the retirement of Nancy J. Hutson, Ph.D., from its Board of Directors and the election of Vincent J. Milano as the next Chair.

Immunovant (IMVT) Prices $550 Million Offering to Fund Anti-FcRn Pipeline Development

11 Dec 2025 SEC Filing 8-K $IMVT

Immunovant (IMVT) Prices $550 Million Offering to Fund Anti-FcRn Pipeline Development

Immunovant (IMVT) priced a $550 million stock offering to fund clinical trials for IMVT-1402 and batoclimab across multiple autoimmune indications.

Immunovant (IMVT) Prices $550 Million Stock Offering to Fund Anti-FcRn Therapy Development

11 Dec 2025 SEC Filing 8-K $IMVT

Immunovant (IMVT) Prices $550 Million Stock Offering to Fund Anti-FcRn Therapy Development

Immunovant (IMVT) priced a $550M stock offering to fund development of IMVT-1402 across six autoimmune indications.

Citius Oncology (CTOR) Secures $18 Million Financing Following FDA Approval of LYMPHIR

11 Dec 2025 SEC Filing 8-K $CTOR

Citius Oncology (CTOR) Secures $18 Million Financing Following FDA Approval of LYMPHIR

Citius Oncology (CTOR) closed an $18 million offering after FDA approval of its CTCL drug LYMPHIR, per an 8-K filed Dec 10, 2025.

Structure Therapeutics (GPCR) Completes $650 Million Follow-On Offering

11 Dec 2025 SEC Filing 8-K Financing $GPCR

Structure Therapeutics (GPCR) Completes $650 Million Follow-On Offering

Structure Therapeutics Inc. (GPCR) completed a $650 million follow-on public offering of ADSs and pre-funded warrants.